Degesys A - Search Results

1

Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine Tumor.

Carter CA, Degesys A, Oronsky B, Scicinski J, Caroen SZ, Oronsky AL, Reid T, Cabrales P, Roswarski J. Carter CA, et al. Among authors: degesys a. Case Rep Oncol. 2015 Oct 30;8(3):461-5. doi: 10.1159/000441775. eCollection 2015 Sep-Dec. Case Rep Oncol. 2015. PMID: 26600780 Free PMC article.

2

RRx-001-Induced Tumor Necrosis and Immune Cell Infiltration in an EGFR Mutation-Positive NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors: A Case Report.

Brzezniak C, Schmitz BA, Peterson PG, Degesys A, Oronsky BT, Scicinski JJ, Caroen SZ, Carter CA. Brzezniak C, et al. Among authors: degesys a. Case Rep Oncol. 2016 Jan 15;9(1):45-50. doi: 10.1159/000443605. eCollection 2016 Jan-Apr. Case Rep Oncol. 2016. PMID: 26933418 Free PMC article.

3

Partial Response to Platinum Doublets in Refractory EGFR-Positive Non-Small Cell Lung Cancer Patients after RRx-001: Evidence of Episensitization.

Carter CA, Oronsky BT, Caroen SZ, Scicinski JJ, Cabrales P, Reid T, Degesys A, Jenkins J, Brzezniak C. Carter CA, et al. Among authors: degesys a. Case Rep Oncol. 2016 Jan 28;9(1):62-7. doi: 10.1159/000443725. eCollection 2016 Jan-Apr. Case Rep Oncol. 2016. PMID: 26933421 Free PMC article.

4

Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001.

Carter CA, Schmitz B, Peterson PG, Quinn M, Degesys A, Jenkins J, Oronsky B, Scicinski J, Caroen S, Reid TR, Cabrales P, Brzezniak C. Carter CA, et al. Among authors: degesys a. Case Rep Oncol. 2016 Mar 10;9(1):164-70. doi: 10.1159/000444633. eCollection 2016 Jan-Apr. Case Rep Oncol. 2016. PMID: 27065848 Free PMC article.

5

RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets.

Carter CA, Oronsky BT, Caroen SZ, Scicinski JJ, Degesys A, Kim MM, Oronsky AL, Lybeck H, Cabrales P, Oronsky N, Reid T, Roswarski J, Brzezniak C. Carter CA, et al. Among authors: degesys a. Case Rep Oncol. 2016 Mar 11;9(1):171-6. doi: 10.1159/000444631. eCollection 2016 Jan-Apr. Case Rep Oncol. 2016. PMID: 27065849 Free PMC article.

6

Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC.

Carter CA, Oronsky B, Caroen S, Scicinski J, Cabrales P, Degesys A, Brzezniak C. Carter CA, et al. Among authors: degesys a. Respir Med Case Rep. 2016 Apr 24;18:62-5. doi: 10.1016/j.rmcr.2016.04.007. eCollection 2016. Respir Med Case Rep. 2016. PMID: 27330954 Free PMC article.

7

Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets.

Carter CA, Oronsky B, Caroen S, Scicinski J, Degesys A, Cabrales P, Reid TR, Brzezniak C. Carter CA, et al. Among authors: degesys a. Case Rep Oncol. 2016 May 24;9(2):285-9. doi: 10.1159/000446209. eCollection 2016 May-Aug. Case Rep Oncol. 2016. PMID: 27403127 Free PMC article.

8

Conversion of Platinum-Etoposide-Resistant to Sensitive SCLC after Treatment with the Epi-Immunotherapeutic RRx-001: A Case Report.

Brzezniak C, Oronsky B, Scicinski J, Caroen S, Cabrales P, Dean Abrouk N, Kim MM, Brown JF, Reid TR, Larson C, Oronsky A, Day R, Degesys A, Carter CA. Brzezniak C, et al. Among authors: degesys a. Oncol Res Treat. 2016;39(11):720-723. doi: 10.1159/000449432. Epub 2016 Sep 19. Oncol Res Treat. 2016. PMID: 27855386

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

8 results

Search Page

Filters